NIH Probing Use of Fetal Tissue

WASHINGTON—NIH is looking into charges that it has improperly funded research on tissues and organs that have been removed from live human fetuses. The investigation stems from allegations by Jeremy Rifkin of the Foundation on Economic Trends, that the National Disease Research Interchange (NDRI) is not following appropriate protocols to establish death before obtaining the tissue and providing it to researchers. F. William Dommel, of NIH’s Office of Protection from Research Risk

Written byElisabeth Carpenter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—NIH is looking into charges that it has improperly funded research on tissues and organs that have been removed from live human fetuses.

The investigation stems from allegations by Jeremy Rifkin of the Foundation on Economic Trends, that the National Disease Research Interchange (NDRI) is not following appropriate protocols to establish death before obtaining the tissue and providing it to researchers. F. William Dommel, of NIH’s Office of Protection from Research Risks, said the investigation’s scope and speed will depend in part on the material made available by Rifkin’s group.

Ongoing research in fetal tissue transplantation promises the possibility of new treatments for a range of diseases including diabetes and Parkinson's Don Ralbovsky, an NIH spokesman, estimated that fewer than five scientists nationwide are working with human fetal transplants on NIH grants. Some one percent of the 9,000 tissues the NDRI will this year come from fetuses.

"What we're talking ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies